The PDE5 inhibitors have recently been found to have cognitive-enhancing effects in animal models. To investigate the efficacy of repeated dosing with a PDE5 inhibitor on cognitive function and somatization in patients with erectile dysfunction, 27 patients with erectile dysfunction received udenafil (100 mg) at 3-day intervals for 2 months. The international index of erectile function-5 (IIEF-5), a cognitive battery (the Korean version of mini-mental state examination (K-MMSE), the frontal assessment battery (K-FAB), the Seoul verbal learning test) and a physical health questionnaire-15 (PHQ-15) were performed at baseline and at 2 months, following the administration of udenafil. The patients were divided on the basis of their IIEF-5 score into responders (change47) and non-responders. The mean IIEF-5 score was significantly increased after treatment (7.92±3.83 to 16.33±4.75, Po0.001). The scores of K-MMSE (27.03±1.58 to 28.07±1.57, P ¼ 0.001), K-FAB (13.65 ± 1.96 to 15.41 ± 1.85, Po0.001) and PHQ-15 (18.92 ± 4.96 to 17.63 ± 4.75, P ¼ 0.003) were significantly improved after treatment. In addition, the responders (n ¼ 16) had more improved cognitive function (r ¼ 0.603, P ¼ 0.001) and somatization (r ¼ À0.402, P ¼ 0.038) than non-responders (n ¼ 11). Repeated dosing with a PDE5 inhibitor seems to improve cognitive function and somatization, as well as erectile function in patients with erectile dysfunction.
Introduction
Orally administrated PDE5 inhibitors competitively inhibit PDE5, which physiologically inactivates cyclic guanosine monophosphate (cGMP) in the erectile bodies. Thus, PDE5 inhibitors increase nitric oxide-stimulated cGMP concentration in patients with erectile dysfunction. 1 Three PDE5 inhibitors (sildenafil, tadalafil and vardenafil) have been widely used. Udenafil (Zydena), which is the most recently developed PDE5 inhibitor, is also used in some countries, such as Korea, Russia, Ukraine and Malaysia, because of the reported safety and efficacy of udenafil in the treatment of erectile dysfunction. [2] [3] [4] The PDE5 inhibitors are commonly used for erectile dysfunction, but there have been several different attempts to evaluate additional beneficial effect of PDE5 inhibitors in treatments for pulmonary hypertension, 5 benign prostate hyperplasia 6 and stroke. 7 In a recent study, PDE5 has been identified in the rat brain, including the cortex and hippocampus. 8, 9 PDE5 inhibitors readily cross the blood-brain barrier and increase cGMP concentrations in the intracellular pathway activated by N-methy-D-aspartic acid receptors, which is believed to mediate long-term potentiation and memory consolidation. [10] [11] [12] Thus, some valuable animal models have been utilized to confirm the cognitive-enhancing effect of PDE5 inhibitors. Subchronic administration of sildenafil has been shown to increase cortical cGMP levels 13 and sildenafil reversed cognitive deficits in rats produced by diabetes, 14 anticholinergics 15 and hyperammonemia. 10 Despite positive findings in animal models, in vivo data are limited and no conclusive remarks can be made. There has been only one study, as far as we know, to investigate the impact of a PDE5 on cognitive function in humans, with a double-blind design along with only a single dose. A single dose of sildenafil (50 or 100 mg) was shown not to have an effect on putative N-methy-D-aspartic acid receptor-mediated memory deficits in schizophrenia patients. It was suggested that the doses used in the study were not optimal and repeated dosing may be necessary to achieve therapeutic effects. 16 Therefore, we conducted this study to assess whether or not repeated dosing with a PDE5 inhibitor improves cognitive function and somatization, as well as erectile function in patients with erectile dysfunction.
Materials and methods
The study was conducted at the Clinical Trials Centre of the Catholic University of Korea. The study protocol was approved by the Institutional Review Board. All procedures were performed in accordance with the recommendation of the Declaration of Helsinki on biomedical research involving human subjects. All subjects gave written informed consent before being enrolled.
Subjects
The inclusion criteria were as follows: (1) male patients between 40 and 70 years of age, (2) patients who complained of erectile dysfunction for a minimum of 3 months, (3) patients who had a regular female sex-partner during the study, (4) patients whose international index of erectile function-5 (IIEF-5) score was o21 points on a screening test and (5) patients who did not complain of cognitive impairment. Erectile dysfunction was defined as an inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance. 17 The severity of erectile dysfunction was classified based on baseline IIEF erectile function domain score into mild (17) (18) (19) (20) (21) , mild to moderate (12) (13) (14) (15) (16) , moderate (8) (9) (10) (11) and severe (5-7). 18 The etiology of erectile dysfunction was determined by the study investigator based on patient history, as well as physical and laboratory examination findings. Exclusion to study participation included (1) history of a cerebral vascular accident, myocardial infarction, achromatopsia, dyschromatopsia, retinitis pigmentosa, head trauma, psychiatric disorder and dementia (according to DSM-IV or whose MMSE scores were o24), (2) patients who were currently taking drugs that inhibited or induced hepatic cytochrome P4503A4, PDE5 inhibitors, nitrates, a-blockers, antidepressants or other neuropsychiatric medication and (3) patients who were not willing to use appropriate methods of contraception with their sex partners or patients and their sex partners were planning to achieve pregnancy.
Study design
Thirty-three men who were diagnosed with erectile dysfunction by clinical history and physical examination were enrolled in this prospective study. After erectile dysfunction had been confirmed, an electocardiography was obtained. Patients were scheduled for three sessions at 1-month intervals. At baseline, we administered the IIEF-5 for erectile dysfunction, physical health questionnaire (PHQ)-15 for somatization and a cognitive battery for cognition. The PHQ-15 is a somatic symptom severity subscale. It assesses 15 somatic symptoms or symptom clusters that account for more than 90% of all physical complaints (excluding upper respiratory tract symptoms) reported by outpatients. Each item is rated on a scale from 0 to 2. Scoring simply requires adding the numbers circled, and scores can range from 0 to 30. The PHQ-15 has already been validated in primary-care settings. 19, 20 The cognitive battery consisted of the Korean version of the minimental state examination (K-MMSE) for general cognitive function, 21 the Seoul verbal learning test (SVLT) for episodic memory and learning 22 and the Korean version of the frontal assessment battery (K-FAB) for frontal executive function. 23 The SVLT is the modified Korean version of the Hopkins verbal learning test, 24 and by performing the SVLT, scores of three trials and delayed recalls were recorded for the evaluation of learning and memory consolidation.
Following the initial baseline evaluation, patients were given udenafil (100 mg) every 3 days for 1 month, after which the patients had a follow-up evaluation (second visit). This was followed by an assessment of the IIEF-5 and adverse events. After the assessment, patients were given udenafil (100 mg) for another month and the IIEF-5, adverse events, the physical health questionnaire-15 (PHQ-15), and cognitive battery were administered (third visit).
Subjects were divided into two groups (responder and non-responder) according to the change in IIEF-5 at third visit. Subjects with an increase in the IIEF-5 score (47) were considered to be responders. 4 Statistical analysis Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS Effect of repeated dosing with udenafil on cognition, somatization and erection YS Shim et al version 15.0. for Windows; SPSS Inc., Chicago, IL, USA). Continuous data were reported as the mean±s.d. Changes from baseline to the end of treatment were assessed using the Wilcoxon signedrank test. The age and disease duration distributions, and the results of baseline evaluations, such as the IIEF-5, PHQ-15, K-MMSE, SVLT, and K-FAB and the changes after treatment, were compared between the responder and non-responder groups using the Mann-Whitney U-test. Spearman correlation analysis was performed for changes in evaluation scores of erectile dysfunction, somatization and cognitive functions after medication. A 5% level of significance was used for all statistical testing.
Results
Thirty-three patients were enrolled in the study and 27 patients completed the study. One patient dropped out due to hot flushing at second visit and five patients were lost at follow-up (two patients at second visit and three patients at third visit were significantly improved after treatment. However, there were no differences in the SVLT total and delayed recall after treatment (Table 2) . Sixteen patients had a change in an IIEF-5 score 47 (responder) and 11 patients had the change in an IIEF-5 score p7 (non-responder) at the end of treatment. Age and dysfunction duration were not different between the two groups. The results of baseline evaluations of IIEF-5, K-MMSE, SVLT, K-FAB and PHQ-15 were also not different. After medication, the mean score changes of IIEF-5 were 10.56±2.65 in the responder group and 5.18±1.60 in the non-responder group (Po0.001). The results of the K-MMSE (responder, 1.56 ± 1.36 versus nonresponder, 0.27±1.56; P ¼ 0.024) and PHQ-15 (responder, À2.00±1.75 versus non-responder, À0.36 ± 2.20; P ¼ 0.042) were different between the two groups. The improvement in the K-MMSE and PHQ-15 scores were significant in the responders (Table 3 ). Correlation analysis showed that the change in IIEF-5 scores correlated with the change in K-MMSE (r ¼ 0.603, P ¼ 0.001) and PHQ-15 scores (r ¼ À0.402, P ¼ 0.038).
Most patients tolerated udenafil therapy well. No medication-related severe adverse events were observed, but 2 of 27 patients reported mild dizziness. No patients discontinued udenafil therapy.
Discussion
Several studies have suggested that PDE5 inhibitors might improve cognition by increasing the concentration of cGMP in rat brains. [12] [13] [14] [15] However, there has been only one study that has tested the effect of PDE5 inhibitor on cognition in human subjects, especially with psychiatric disorders. 16 In contrast with anecdotal studies, our study was conducted in healthy volunteers without psychiatric disorders. Abbreviations: IIEF-5, the international index of erectile function-5; K-FAB, the Korean version of the frontal assessment battery; K-MMSE, the Korean version of the mini-mental state examination; PHQ-15, the physical health questionnaire-15; SVLT, the Seoul verbal learning test.
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Our study demonstrated that udenafil seems to improve general cognition and decreases somatization in patients with erectile dysfunction, but a clear explanation for this positive finding is not known. The possible mechanism by which udenafil improves general cognition and decreases somatization in patients with erectile dysfunction may be that (1) PDE5 inhibitors are believed to enhance memory and learning via facilitation of long-term potentiation mediated by the glutamate-nitric oxidecGMP intracellular pathway. The cGMP-activated protein kinase is thought to mediate memory consolidation via phosphorylation and protein formation. ( 2) The cGMP is a known vasodilator and the effects of PDE inhibition on cognitive function could be explained by enhancement of cerebrovascular function and the delivery of glucose and oxygen to the brain. (3) Taking a PDE 5 inhibitor improves erection, which ameliorates depression or anxiety, enhances self-confidence and thus promotes cognition and general health.
There are only a few studies that have investigated the association between PDE5 inhibitors and cerebral blood flow. Rutten et al. 25 concluded that PDE5 inhibitors enhanced memory for objects and locations by increasing cGMP levels in rodents. However, this memory-enhancing effect of PDE5 inhibitors is independent of cerebral blood flow and glucose metabolism. Arnavaz et al. 26 also reported that neither the intake of sildenafil nor the application of placebo results in any significant changes in blood flow velocity of the right middle cerebral artery in human subjects. Because we did not measure the possible changes in blood flow velocity of cerebral artery, we currently have no clinical data to prove whether the PDE5 inhibitors can improve cerebral blood flow. However, the improvement in cognitive function observed in the present study may not likely be associated with increment of blood flow velocity in cerebral vasculature based on previous studies. There is an increasing body of evidence to support the concept that feelings of depression in patients with erectile dysfunction may be resolved with optimal erectile dysfunction therapy. Hatzichristou et al. 27 demonstrated that the symptoms of depression were statistically reduced in the valdenafil treatment group compared with the placebo group, and significantly more patients in the valdenafil treatment group reported an improvement in self-confidence. Another study demonstrated that significant improvements in erectile function and depression occurred in patients treated with vardenafil versus placebo. Treatment of erectile dysfunction should be considered a component of therapy for men with depression and erectile dysfunction. 28 In our present study, the improvement of cognitive function may be closely linked to the improvement of depression and self-confidence, but there are different views on how cognitive dysfunction and depression are related. A classical viewpoint is that cognitive deficits are a net result of depression. Regardless of the cause, cognitive dysfunctions in depression appear to be common and can be proven with a series of cognitive tests. 29 However, we have to consider that a bidirectional relationship between cognition and depression may have also been proposed in anecdotal studies. Another consideration would be that all subjects were not blinded to the treatment. Hence, the results might have been influenced by several hidden clinical factors such as amelioration of anxiety or performance anxiety over the study period. 30 Based on an IIEF-5 cutoff score of 7 points, patients were divided into two groups, which were the responder and non-responder groups. There was a significant difference in the change in cognitive function between the two groups. In the responder group, cognitive function significantly improved. In the current study, an IIEF-5 score of 7 points was set as the cutoff value. To date, in association with the changes in the IIEF score, there is no precise definition of 'responders' to oral PDE5 inhibitors. Paick et al. 4 conducted a placebo-controlled study involving 167 patients in which they reported that the mean changes in IIEF-5 scores from baseline were 7.52 following 12 weeks of udenafil (100 mg). Accordingly, we divided patients into the responder Effect of repeated dosing with udenafil on cognition, somatization and erection YS Shim et al and the non-responder groups based on an IIEF-5 score of 7 points. Little is known about the exact mechanisms by which cognitive functions further increased in the responder group, but the possible mechanism may be that significant differences in the distribution and number of PDE5 receptors in the erectile body and brain between the two groups exist. Additionally, as erectile function improved, there was a corresponding improvement in depressive symptoms and self-confidence, which might have an effect on cognitive function. In animal studies, cognitive effects have been demonstrated with single and repeated dosing of PDE5 inhibitors. However, in a placebo-controlled study of the effects of sildenafil on cognition in patients with schizophrenia, a single dose of sildenafil (50 or 100 mg) did not have an effect on cognitive function. 16 It was suggested that the doses used were not optimal and repeated dosing with sildenafil may be required to produce cognitive and behavioral effects. Accordingly in the current study, repeated administration of udenafil seemed to be effective in enhancing cognitive function. Despite the generally favorable results of our study, there were some limitations that should be addressed. However, significant improvement of K-MMSE and PHQ-15 total score after treatment should be interpreted with caution as the magnitude of improvement in each rating scale was only one point (4.1 and 6.9% from baseline to the end of treatment, respectively). Although the differences were statistically significant, there was a limitation in translation into clinical practice as we had no currently available evidence that only one point difference may correspond to substantial improvement in clinical symptoms. However, we conducted this study targeting healthy volunteers without cognitive deficit and other psychiatric disorders and this point should be reflected in the interpretation of the results. Further studies will definitely be needed on this issue. Furthermore, our findings were based on a relatively small sample size and a nonrandomized design without a placebo control group. Thus, considering the study limitations, a long-term, multicenter, placebo-controlled trial should be performed to further determine the effects of udenafil on cognitive function and somatization in patients with erectile dysfunction, and we are planning to commence a placebo-controlled trial. In addition, we have observed that patients showed improvement of K-MMSE for general cognition after udenafil therapy. However, there was no improvement of SVLT for verbal episodic memory and learning in the present study. This suggests that cognitive domains other than verbal episodic memory may be improved and could have resulted in the improvement of the K-MMSE score, which is a representative of general cognition. The schizophrenia studies included the variable cognitive tests such as fluency, spatial span and logical memory, in addition to the cognitive tests of our study. We examined general cognition, frontal executive function, and verbal memory and learning as a pilot study. Based on the present study, we hope further research will be conducted, including more comprehensive cognitive assessments.
Although improvement in general cognition and somatization was demonstrated, we cannot provide a clear explanation on the potential mechanisms of this finding. Therefore, the measurement of cerebral blood flow and cerebral metabolism with comprehensive neuropsychometric assessments is essential to determine the precise mechanisms of cognitiveenhancing effects with PDE5 inhibitors in human.
Conclusion
Udenafil seems to improve cognitive function and somatization, as well as erectile function without adverse side effects in patients with erectile dysfunction. In particular, improvement in the IIEF-5 scores correlated with the scores of the MMSE and PHQ-15. However, our study is based on a relatively small number of patients and a non-randomized design without a placebo group, thus a multicenter, placebo-controlled trial is necessary to determine the effect of repeated dosing with PDE5 inhibitors on cognition and somatization in patients with erectile dysfunction.
